Form 8-K/A SERA PROGNOSTICS, INC. For: Apr 11
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K/A
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 11, 2022
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
(Address of principal executive offices) | (zip code) |
Registrant’s telephone number, including area code: (801 ) 990-0520
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
The |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging Growth Company x
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
As previously reported on the Current Report on Form 8-K (the “Original Filing”) filed by Sera Prognostics, Inc. (the “Company”) on April 12, 2022, the Company’s Board of Directors (the “Board”) appointed Jane Barlow, M.D., as a new director of the Company, effective as of April 11, 2022.
At the time of the Original Filing, the Board had not made a determination regarding any committee assignments for Dr. Barlow. This amended Current Report on Form 8-K is being filed to provide the committee assignment information omitted from the Original Filing. On June 27, 2022, the Board appointed Dr. Barlow to the nominating and governance committee of the Board, effective immediately.
Other than the preceding disclosure, no other disclosure reported in the Original Filing is amended pursuant to this Report.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
SERA PROGNOSTICS, INC. | ||||||||
By: | /s/ Jay Moyes | |||||||
Jay Moyes | ||||||||
Chief Financial Officer |
Date: June 29, 2022
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Decisions of Annual General Meeting in SP Group A/S
- Cannabix’s Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA
- Nitric Acid Market to Reach USD 36.62 Billion by 2031, Driven by Surging Demand for Fertilizers and Lightweight Vehicles
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!